Prediction of Warfarin Maintenance Dose in Han Chinese Patients Using a Mechanistic Model Based on Genetic and Non-Genetic Factors

Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors

(2011) H. K. Crewe et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians

(2011) Ivet M Suriapranata et al.   BMC Medical Genetics

The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors

(2011) Steven Lane et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy

(2011) P J Avery et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Development of a Bayesian Forecasting Method for Warfarin Dose Individualisation

(2011) Daniel F. B. Wright et al.   PHARMACEUTICAL RESEARCH

Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation

(2011) Inna Y. Gong et al.   PLoS One

A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age

(2010) A-K Hamberg et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of Single-Dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers

(2010) A Frymoyer et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs

(2009) A Choppin et al.   BRITISH JOURNAL OF PHARMACOLOGY

Interactive Modeling for Ongoing Utility of Pharmacogenetic Diagnostic Testing: Application for Warfarin Therapy

(2009) M. W. Linder et al.   CLINICAL CHEMISTRY

A Comprehensive Model for the Humoral Coagulation Network in Humans

(2009) T Wajima et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates

(2009) Masoud Jamei et al.   Drug Metabolism and Pharmacokinetics

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

(2009) Eunice Yuen et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant

(2009) M. G. McDonald et al.   MOLECULAR PHARMACOLOGY

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement

(2008) D. Wang et al.   BLOOD

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

(2008) G. M. Cooper et al.   BLOOD

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

(2008) BF Gage et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetic Determinants of Response to Warfarin during Initial Anticoagulation

(2008) Ute I. Schwarz et al.   NEW ENGLAND JOURNAL OF MEDICINE